Trials / Unknown
UnknownNCT03907228
Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of RHT-3201 for the Evaluation of Efficacy and Safety on the Children With Atopic Dermatitis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- 1 Year – 12 Years
- Healthy volunteers
- Not accepted
Summary
The study's objective is to confirm that RHT-3201 reduces the signs and symptoms of moderate atopic dermatitis determined by SCORAD, in patients aged 1 to 12 years, as compared to placebo. It will also be examined if the RHT-3201 treatment, as compared to placebo, reduces the quantity of topical steroids used to treat disease flares
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | RHT-3201 | PROBIOTIC |
Timeline
- Start date
- 2019-03-15
- Primary completion
- 2020-04-01
- Completion
- 2020-05-01
- First posted
- 2019-04-08
- Last updated
- 2019-04-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03907228. Inclusion in this directory is not an endorsement.